Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| AADvac1 | Axon peptide 108 conjugated to KLH | Alzheimer's Disease (Phase 2), Progressive Nonfluent Aphasia (Phase 1) | Axon Neuroscience SE | Tau | Immunotherapy (active) | |
| AAV2-BDNF | MCI due to AD (Phase 1), Alzheimer's Disease (Phase 1) | Other | DNA/RNA-based | |||
| ABBV-552 | Alzheimer's Disease (Phase 1) | AbbVie | Other | Small Molecule | ||
| ABBV-1088 | Parkinson's Disease (Phase 1) | AbbVie | Other | Small Molecule | ||
| ACD856 | Alzheimer's Disease (Phase 1) | AlzeCure Pharma AB | Other | Small Molecule | ||
| ACI-7104.056 | ACI-7104, Affitope PD01A, PD03A |
Parkinson's Disease (Phase 2), Multiple System Atrophy (Phase 1) | AC Immune SA, AFFiRiS AG | alpha-synuclein | Immunotherapy (active) | |
| ADEL-Y01 | Alzheimer's Disease (Phase 1) | ADEL, Inc., Oscotec Inc. | Tau | Immunotherapy (passive) | ||
| AL044 | Alzheimer's Disease (Phase 1) | Alector | Inflammation | Immunotherapy (passive) | ||
| ALIA-1758 | Alzheimer's Disease (Phase 1) | AbbVie, Aliada Therapeutics | Amyloid-Related | Immunotherapy (passive) | ||
| Allopregnanolone | brexanolone, 3α-hydroxy-5α-pregnan-20-one, 3α,5α-tetrahydroprogesterone |
Alzheimer's Disease (Phase 2), Parkinson's Disease (Phase 1) | Other Neurotransmitters, Other | Small Molecule | ||
| ALX-001 | BMS-984923 | Alzheimer's Disease (Phase 1) | Allyx Therapeutics, Inc. | Amyloid-Related, Other Neurotransmitters | Small Molecule | |
| ALZ-101 | Alzheimer's Disease (Phase 1) | Alzinova AB | Amyloid-Related | Immunotherapy (active) | ||
| ANPD001 | DANPC (dopaminergic neuron precursor cell) | Parkinson's Disease (Phase 1) | Aspen Neuroscience | Other Neurotransmitters | Other | |
| APNmAb005 | RAA7 | Alzheimer's Disease (Phase 1) | Aprinoia Therapeutics | Tau | Immunotherapy (passive) | |
| ARV-102 | Parkinson's Disease (Phase 1) | Arvinas, Inc. | Other | Small Molecule | ||
| AS-S603 | Alzheimer's Disease (Phase 1), Mild Cognitive Impairment (Phase 1) | Amyloid Solution Inc. | Amyloid-Related, Tau | Small Molecule | ||
| ASN90 | ASN120290, ASN-561 |
Progressive Supranuclear Palsy (Phase 1) | Asceneuron SA | Tau | Small Molecule | |
| ATB2005A | ATC161 | Alzheimer's Disease (Phase 1), Progressive Supranuclear Palsy (Phase 1) | Autotac Bio Inc. | Tau | Small Molecule | |
| Atomoxetine | ATX, Strattera |
Alzheimer's Disease (Phase 2), Parkinson's Disease (Phase 1) | Eli Lilly & Co. | Other Neurotransmitters | Small Molecule | ADHD in US |
| AV-1959D | AV-1959 | Alzheimer's Disease (Phase 1) | Amyloid-Related | Immunotherapy (active) | ||
| AV-1980R/A | AV-1980R | Alzheimer's Disease (Phase 1) | Tau | Immunotherapy (active) | ||
| Baricitinib | Olumiant®, NCB28050, LY3009104 |
Alzheimer's Disease (Phase 2), Amyotrophic Lateral Sclerosis (Phase 1) | Eli Lilly & Co. | Inflammation | Small Molecule | Rheumatoid arthritis, Eczema (Europe, Japan only) |
| Bemdaneprocel | BRT-DA01, MSK-DA01 |
Parkinson's Disease (Phase 1) | Bayer, BlueRock Therapeutics | Other Neurotransmitters, Other | Other | |
| Bepranemab | UCB0107, UCB 0107, Antibody D |
Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) | Hoffmann-La Roche, UCB S.A. | Tau | Immunotherapy (passive) | |
| BIIB080 | IONIS-MAPTRx, ISIS 814907 |
Alzheimer's Disease (Phase 1) | Biogen, IONIS Pharmaceuticals | Tau | DNA/RNA-based | |
| BIIB118 | PF-05251749 | Alzheimer's Disease (Phase 1), Parkinson's Disease (Phase 1) | Biogen | Other | Small Molecule | |
| Blarcamesine | Anavex 2-73 | Alzheimer's Disease (Phase 2/3), Parkinson's Disease Dementia (Phase 2), Parkinson's Disease (Phase 1) | Anavex Life Science Corp. | Other | Small Molecule | |
| BT-267 | BT-0267 | Parkinson's Disease (Phase 1) | Brenig Therapeutics | Other | Small Molecule | |
| COYA 302 | IL2 plus Abatacept | Amyotrophic Lateral Sclerosis (Phase 1), Frontotemporal Dementia (Phase 1) | Coya Therapeutics | Inflammation | Combination, Other | |
| CpG 1018® | CpG oligodeoxynucleotides, CpG ODN |
Alzheimer's Disease (Phase 1) | Dynavax Technologies | Amyloid-Related, Inflammation | Immunotherapy (active), DNA/RNA-based | |
| CS6253 | Cogpep™, CS-6253 |
Alzheimer's Disease (Phase 1) | Artery Therapeutics, Inc. | Amyloid-Related, Cholesterol | Small Molecule | |
| E2511 | Alzheimer's Disease (Phase 1) | Eisai Co., Ltd. | Cholinergic System | Small Molecule | ||
| Edicotinib | JNJ-40346527, JNJ-527, PRV-6527 |
Alzheimer's Disease (Phase 1) | Janssen | Inflammation | Small Molecule | |
| Efavirenz | Efavirenz | Alzheimer's Disease (Phase 1) | Amyloid-Related, Tau, Cholesterol | Small Molecule | HIV infection | |
| Empagliflozin | Jardiance, BI-10773 |
Alzheimer's Disease (Phase 1) | Boehringer Ingelheim, Eli Lilly & Co. | Other | Small Molecule | Type 2 Diabetes, Cardiovascular disease |
| Emtricitabine | Alzheimer's Disease (Phase 1) | Gilead Sciences, Inc. | Inflammation | Small Molecule, DNA/RNA-based | HIV infection, Hepatitis B infection | |
| Focused Ultrasound – Blood-Brain Barrier | FUS-BBB, MRgFUS, MRI-Guided Focused Ultrasound, FUS+MB |
Alzheimer's Disease (Phase 1), Amyotrophic Lateral Sclerosis (Phase 1), Mild Cognitive Impairment (Phase 1), Parkinson's Disease (Phase 1) | Amyloid-Related, Other | Procedural Intervention | ||
| GC021109 | Alzheimer's Disease (Phase 1) | GliaCure | Inflammation | Small Molecule | ||
| Gemfibrozil | Lopid, Jezil, Gen-Fibro |
Alzheimer's Disease (Phase 1) | Cholesterol | Small Molecule | Hyperlipidemia | |
| GSK2647544 | GSK-2647544 | Alzheimer's Disease (Phase 1) | GlaxoSmithKline (GSK) | Cholesterol | Small Molecule | |
| GT-02287 | Parkinson's Disease (Phase 1) | Gain Therapeutics, Inc. | alpha-synuclein, Other | Small Molecule | ||
| IBC-Ab002 | Alzheimer's Disease (Phase 1) | ImmunoBrain Checkpoint | Amyloid-Related, Inflammation, Other | Immunotherapy (passive) | ||
| KP405 | DA5-CH | Parkinson's Disease (Phase 1) | Kariya Pharmaceuticals ApS | Other | Small Molecule | |
| Leucettinib-21 | (R,Z)-5-(benzo[d]thiazol-6-ylmethylene)-2-((1-methoxy-4-methylpentan-2-yl)amino)-3,5-dihydro-4H-imidazol-4-one | Alzheimer's Disease (Phase 1), Down's Syndrome (Phase 1) | Perha Pharmaceuticals | Other | Small Molecule | |
| LU AF82422 | Parkinson's Disease (Phase 1), Multiple System Atrophy (Phase 2) | Genmab A/S, Lundbeck | alpha-synuclein | Immunotherapy (passive) | ||
| Lu AF87908 | hC10.2 | Alzheimer's Disease (Phase 1) | Lundbeck | Tau | Immunotherapy (passive) | |
| LY3954068 | Alzheimer's Disease (Phase 1) | Eli Lilly & Co. | Tau | DNA/RNA-based | ||
| LY3962681 | Parkinson's Disease (Phase 1) | Eli Lilly & Co., Prevail Therapeutics | alpha-synuclein | DNA/RNA-based | ||
| MemorEM Transcranial Electromagnetic Treatment | TEMT | Alzheimer's Disease (Phase 1) | NeuroEM Therapeutics, Inc. | Amyloid-Related, Other | Procedural Intervention | |
| Mivelsiran | ALN-APP | Alzheimer's Disease (Phase 1), Cerebral Amyloid Angiopathy (Phase 2) | Alnylam Pharmaceuticals, Inc. | Amyloid-Related | DNA/RNA-based | |
| MK-8189 | Alzheimer's Disease (Phase 1) | Merck | Other Neurotransmitters | Small Molecule | ||
| MW151 | MW01-2-151SRM, Minozac, MW01-2-151WH, compound 17 |
Alzheimer's Disease (Phase 1) | ImmunoChem Therapeutics, LLC | Inflammation | Small Molecule | |
| NB-4746 | Amyotrophic Lateral Sclerosis (Phase 1) | Nura Bio™ Inc. | Other | Small Molecule | ||
| Nicotinamide Riboside | Niagen, NR, Nicotinamide, Vitamin B3 |
Alzheimer's Disease (Phase 1), Parkinson's Disease (Phase 2), Mild Cognitive Impairment (Phase 1/2) | ChromaDex, Others | Other | Supplement, Dietary | |
| NIO752 | Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 1) | Novartis Pharmaceuticals Corporation | Tau | DNA/RNA-based | ||
| NMRA-511 | NMRA-323511 | Alzheimer's Disease (Phase 1) | Neumora | Other | Small Molecule | |
| NPT520-34 | Amyotrophic Lateral Sclerosis (Phase 1), Parkinson's Disease (Phase 1) | Neuropore Therapies, Inc. | alpha-synuclein, Inflammation, Other | Small Molecule | ||
| NTRX-07 | MDA7 | Alzheimer's Disease (Phase 1) | NeuroTherapia, Inc. | Inflammation, Other | Small Molecule | |
| NUZ-001 | S-Monepantel, Zolvix® |
Amyotrophic Lateral Sclerosis (Phase 1) | Neurizon Therapeutics | Other | Small Molecule | Deworming sheep |
| NX210c | HWSGWSS[CSRSC]GOH (brackets represent the disulfide bond) | Amyotrophic Lateral Sclerosis (Phase 2), Parkinson's Disease (Phase 1) | Axoltis Pharma | Other | Small Molecule | |
| OLX-07010 | Alzheimer's Disease (Phase 1) | Oligomerix, Inc. | Tau | Small Molecule | ||
| OPM-201 | S221237 | Parkinson's Disease (Phase 1) | Oncodesign Precision Medicine | Other | Small Molecule | |
| PMN310 | Alzheimer's Disease (Phase 1) | ProMIS Neurosciences, Inc. | Amyloid-Related | Immunotherapy (passive) | ||
| PRI-002 | Contraloid, contraloid acetate, RD2 |
Alzheimer's Disease (Phase 1) | Priavoid GmbH | Amyloid-Related | Small Molecule | |
| Protollin | Alzheimer's Disease (Phase 1) | I-MAB Biopharma Co., Ltd., Jiangsu Nhwa Pharmaceutical Co., Ltd | Inflammation | Immunotherapy (active) | ||
| QRL-101 | QRA-244 | Amyotrophic Lateral Sclerosis (Phase 1) | QurAlis Corporation | Other | Small Molecule | |
| QRL-201 | Amyotrophic Lateral Sclerosis (Phase 1) | QurAlis Corporation | Other | DNA/RNA-based | ||
| REM0045392 | REM392 | Alzheimer's Disease (Phase 1) | remynd | Tau | Small Molecule | |
| S-Equol | Aus-131 | Alzheimer's Disease (Phase 1) | Ausio Pharmaceuticals, LLC | Other | Small Molecule | |
| SAR446159 | ABL301, SynucleinxIGF1R mAb |
Parkinson's Disease (Phase 1) | ABL Bio, Inc., Sanofi | alpha-synuclein | Immunotherapy (passive) | |
| Saracatinib | AZD0530 | Alzheimer's Disease (Discontinued), Parkinson's Disease (Phase 1) | AstraZeneca | Other | Small Molecule | |
| Sargramostim | GM-CSF Leukine , Leukine® |
Alzheimer's Disease (Phase 2), Parkinson's Disease (Phase 1) | Genzyme, Partner Therapeutics, Inc., Sanofi | Inflammation, Other, Unknown | Other | Bone Marrow Stimulation |
| Selnoflast | RO7486967, RG-6418, IZD-334, somalix |
Parkinson's Disease (Phase 1) | Hoffmann-La Roche, Inflazome Ltd. | Inflammation | Small Molecule | |
| SNP318 | Alzheimer's Disease (Phase 1) | SciNeuro Pharmaceuticals | Inflammation | Small Molecule | ||
| SUVN-G3031 | Samelisant, 17v |
Alzheimer's Disease (Phase 1) | Suven Life Sciences Ltd | Cholinergic System, Other Neurotransmitters | Small Molecule | |
| TAK-341 | MEDI1341 | Parkinson's Disease (Phase 1), Multiple System Atrophy (Phase 2) | AstraZeneca, Takeda Pharmaceutical Company | alpha-synuclein | Immunotherapy (passive) | |
| TB006 | Alzheimer's Disease (Phase 1) | TrueBinding, Inc. | Inflammation | Immunotherapy (passive) | ||
| THN391 | Alzheimer's Disease (Phase 1) | Therini Bio®, Inc. | Inflammation | Immunotherapy (passive) | ||
| TPI 287 | Alzheimer's Disease (Inactive), Corticobasal Degeneration (Inactive), Progressive Supranuclear Palsy (Phase 1) | Cortice Biosciences | Tau | Small Molecule | ||
| UCB7853 | Parkinson's Disease (Phase 1) | UCB S.A. | alpha-synuclein | Immunotherapy (passive) | ||
| Verdiperstat | AZD3241, BHV-3241 |
Motor Neuron Disease (Discontinued), Multiple System Atrophy (Discontinued), Primary Progressive Aphasia (Phase 1) | AstraZeneca, Biohaven Pharmaceuticals | Inflammation, Other | Small Molecule | |
| VG-3927 | Alzheimer's Disease (Phase 1) | Vigil Neuroscience, Inc. | Amyloid-Related, Inflammation | Small Molecule | ||
| VHB937 | Alzheimer's Disease (Phase 1), Amyotrophic Lateral Sclerosis (Phase 2) | Novartis Pharmaceuticals Corporation | Amyloid-Related | Immunotherapy (passive) | ||
| VQ-101 | Parkinson's Disease (Phase 1) | Vanqua Bio | alpha-synuclein, Other | Small Molecule | ||
| VY-TAU01 | HC3LC2, Voyager_9, VY7523 |
Alzheimer's Disease (Phase 1) | Voyager Therapeutics | Tau | Immunotherapy (passive) |